Daily Roundup

MXO.ASX BOE.ASX VAU.ASX CYL.ASX OCC.ASX

Motio Ltd is riding high after posting record revenue in May and June, with June marking the strongest month in the company's history. The health network expansion is tracking well, with Motio Drive set to hit 100 'tops' by late July. Forward bookings for Q1 FY27 are up 20.3%, while first-half forward revenue climbed 8.7%, driven by diversified demand across multiple industry categories. The company is well-positioned for profitable growth as it leverages its established platform into new opportunities.

Gold producers dominated the day's announcements, with several companies hitting their production targets and delivering strong operational results.

Vault Minerals wrapped up FY26 by achieving its full-year production guidance, delivering 336,540 ounces of gold. The company's Q4 performance was particularly impressive, producing 89,338 ounces—a 14% jump quarter-on-quarter. More importantly, Vault kicked off underground development at Sugar Zone on July 1, which will ramp up throughout FY27 ahead of the processing plant restart in Q1 FY28. The miner finished the year in excellent financial shape with $842 million in cash and bullion, zero debt, and no hedges in place. It generated $219 million in underlying free cash flow during the year.

Catalyst Metals Ltd also delivered record results, posting its highest quarterly and annual production since 2013. The company produced 31,812 ounces in Q4 and 104,000 ounces for the full year, hitting its guidance range. Cash and bullion reserves jumped to A$323 million by June 30, up A$46 million from March 31. Like Vault, Catalyst remains debt-free and has an undrawn A$100 million debt facility sitting in reserve, giving it A$423 million in total liquidity. With the Trident gold deposit ramping up, the company expects to contribute around 15,000 to 20,000 ounces per quarter going forward.

Boss Energy met its revised FY26 production guidance, drumming 1.41 million pounds of U3O8. The uranium producer has accelerated its technical studies for the Honeymoon operation and now plans to release an updated feasibility study and JORC Mineral Resource Estimate by the end of August. The company achieved key operational milestones in June that have strengthened its production infrastructure for FY27, and it's planning an in-person Investor Day in September to outline its production ramp-up and long-term strategy.

Orthocell is expanding its international footprint by appointing MediTime as the exclusive distributor for its Remplir nerve repair product in Thailand. The move taps into a US$84 million Thai nerve repair market and builds on the existing partnership with Device Technologies Group, which already handles distribution in Australia, New Zealand, and Singapore. Regulatory approval from the Thai Food and Drug Administration is already in hand.